ELCC 2019

2:03
TKIs to treat EGFRm-positive NSCLC
Marina Garassino
1:16
The promise of stereotactic radiotherapy for oligometastases
Françoise Mornex
1:50
Prof. Kelly’s overview of the RECaN project
Daniel Kelly
1:03
Managing oligometastatic NSCLC with thoracic irradiation
Françoise Mornex
2:06
Afatinib for advanced EGFRm-positive NSCLC
Antonio Passaro
1:50
The evolving role of the nurse in cancer therapy
Celia Diez de los Rios
2:05
Updates from the PROFILE 1001 study
Alice Tsang Shaw
0:42
Second-generation ALK inhibitors in ALK-positive NSCLC
Antonio Passaro
1:42
Recent developments in radiotherapy for lung cancer
Françoise Mornex
0:44
ALK-TKIs: targeted therapies for ALK-positive NSCLC
Antonio Passaro
1:47
Challenges in using ALK inhibitors
Nicolas Girard
1:23
I-O monotherapy for advanced NSCLC
Martin Reck
1:23
NSCLC: a treatment landscape in flux in the checkpoint inhibitor era
Martin Reck
2:10
Combining checkpoint inhibitors with chemotherapy for NSCLC
Marina Garassino
2:21
Current treatment landscape for ALK-positive NSCLC
Marina Garassino
1:31
IMpower150: efficacy outcomes of atezolizumab addition in pre-treated EGFR-mutated NSCLC
Martin Reck
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals